GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Volcano Corp (FRA:VQY) » Definitions » EV-to-Revenue

Volcano (FRA:VQY) EV-to-Revenue : 2.75 (As of Oct. 31, 2024)


View and export this data going back to . Start your Free Trial

What is Volcano EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Volcano's enterprise value is €811.7 Mil. Volcano's Revenue for the trailing twelve months (TTM) ended in Sep. 2014 was €294.9 Mil. Therefore, Volcano's EV-to-Revenue for today is 2.75.

The historical rank and industry rank for Volcano's EV-to-Revenue or its related term are showing as below:

FRA:VQY's EV-to-Revenue is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 3.38
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-10-31), Volcano's stock price is €15.68. Volcano's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2014 was €5.64. Therefore, Volcano's PS Ratio for today is 2.78.


Volcano EV-to-Revenue Historical Data

The historical data trend for Volcano's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Volcano EV-to-Revenue Chart

Volcano Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.19 4.34 3.29 3.10 3.02

Volcano Quarterly Data
Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.34 3.02 2.71 2.80 1.99

Competitive Comparison of Volcano's EV-to-Revenue

For the Medical Devices subindustry, Volcano's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Volcano's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Volcano's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Volcano's EV-to-Revenue falls into.



Volcano EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Volcano's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=811.723/294.893
=2.75

Volcano's current Enterprise Value is €811.7 Mil.
Volcano's Revenue for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €294.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Volcano  (FRA:VQY) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Volcano's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=15.68/5.641
=2.78

Volcano's share price for today is €15.68.
Volcano's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.64.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Volcano EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Volcano's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Volcano Business Description

Traded in Other Exchanges
N/A
Address
Volcano Corp incorporated in the state of Delaware in January 2000. The Company completed its initial public offering on June 15, 2006. The Company designs, develops, manufactures and commercializes a broad suite of precision guided therapy tools including intravascular ultrasound, or IVUS, and fractional flow reserve, or FFR, products. The IVUS products include single-procedure disposable phased array and rotational IVUS imaging catheters, and additional functionality options such as ChromaFlo stent apposition analysis. FFR offerings can be accessed through its multi-modality platforms, and it also provide FFR-only consoles. Its products include: IVUS Products, Catheters, its single-use disposable catheters operate and interface solely with its family of consoles. Catheters, its single-use disposable catheters operate and interface solely with its family of consoles. ChromaFlo stent apposition analysis technology uses sequential IVUS frames to differentiate circulating blood from stationary or anchored tissue. SyncVision, Sync-Rx Ltd, or Sync-Rx, an Israel-based company that develops advanced software applications designed to optimize and facilitate trans-catheter cardiovascular interventions using automated online image processing. FFR products consist of pressure and flow consoles and single-procedure disposable pressure and flow guide wires. The Company's primary imaging competitors globally are Boston Scientific, Inc., or Boston Scientific, with its IVUS offering and St. Jude Medical, Inc., or St. Jude with its OCT offering. In Japan, it also competes with Terumo Corporation, which offers both IVUS and OCT. In the FFR market, its primary competitor is St. Jude. Because of the size of the vascular market opportunities, competitors and potential competitors have dedicated and will continue to dedicate significant resources to aggressively promote their products. It has registered and common law trademarks in the U.S. and elsewhere in the world including, but not limited to, Aim, Axsun, Bi-Trieval, Centriq, ChromaFlo, ComboMap, ComboWire, Core, Crux, Crux Biomedical, Define, Eagle Eye, ETNA, FACT, FloMap, FloWire, Ginko, GlyDx, Hi-Q, iFR, In-Line Digital, Instant Wave-Free Ratio, Intentio, Octave, pcFM, Precision Guided Therapy, PreView, PrimeWire, PrimeWire Prestige, ReFlow, Revolution, SlyDx, s5i, SmartMap, SpinVision, Sync-Rx, Trak Back, Valet, Verrata, VH, VIBE, Virtual Histology, Visions, Volcano, Wavewire, Xtract and Zuum. The Company's medical device products are subject to extensive and rigorous regulation by the FDA, as well as other federal and state regulatory bodies in the U.S. and comparable authorities in other countries.

Volcano Headlines

No Headlines